Phase II trial of cisplatin in small cell carcinoma of the lung

R. M. Levenson, D. C. Ihde, M. S. Huberman, M. H. Cohen, P. A. Bunn, J. D. Minna

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Eighteen patients with histologically documented small cell carcinoma of the lung who had failed initial combination chemotherapy regimens were treated with single-agent cisplatin in a dose of 100 mg/m 2 every 3 weeks, with mannitol and fluid diuresis. Tumor regression was limited to one partial response (response rate, 6%; 95% confidence limits, 1%-27%). Significant toxic effects were gastrointestinal (severe nausea and vomiting in 12 of 14 patients) and hematologic (severe leukopenia in one patient and severe thrombocytopenia in three). The antitumor efficacy of high-dose cisplatin in heavily pretreated patients with small cell carcinoma of the lung appears to be marginal.

Original languageEnglish (US)
Pages (from-to)905-907
Number of pages3
JournalCancer Treatment Reports
Issue number9-10
StatePublished - Nov 6 1981

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II trial of cisplatin in small cell carcinoma of the lung'. Together they form a unique fingerprint.

Cite this